Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

SUZANNE K SWAN

Allopathic & Osteopathic Physicians Internal Medicine Nephrology

NPI
1740223171
CMS profile
782877
Location
MINNEAPOLIS, MN

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2023 · Entire year

$1,623.09

13 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2023 · entire year · sorted by reported total

Nature of paymentAmountRecords
Travel and Lodging $1,013.09 4
Food and Beverage $610.00 9

By paying entity

PY2023 · entire year · sorted by reported total

Paying entityAmountRecords
Boehringer Ingelheim International GmbH $1,623.09 13

Page 1 of 1; records 1–13 of 13 matching records. This page contains 13 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

SUZANNE K SWAN

NPI 1740223171 · CMS profile ID 782877

Allopathic & Osteopathic Physicians / Internal Medicine / Nephrology

MINNEAPOLIS, MN

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–13 of 13 matching records. This page contains 13 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1740223171?year=2023&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
SUZANNE K SWAN, NPI 1740223171, CMS profile ID 782877. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–13 of 13 matching records. This page contains 13 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1740223171?year=2023&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
APA 7
IndustryPayments. (2026). SUZANNE K SWAN, NPI 1740223171, CMS profile ID 782877. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–13 of 13 matching records. This page contains 13 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1740223171?year=2023&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
Bluebook
SUZANNE K SWAN, NPI 1740223171, CMS profile ID 782877, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–13 of 13 matching records. This page contains 13 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1740223171?year=2023&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30

13 matching records · $1,623.09 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 13 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–13 of 13.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Boehringer Ingelheim International GmbH $40.0010/11/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1017331443 CMS
Boehringer Ingelheim International GmbH $50.0010/11/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1017331445 CMS
Boehringer Ingelheim International GmbH $145.0010/11/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1017331447 CMS
Boehringer Ingelheim International GmbH $40.0010/11/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1017331449 CMS
Boehringer Ingelheim International GmbH $40.0010/11/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1017331451 CMS
Boehringer Ingelheim International GmbH $258.2310/11/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1017331453 CMS
Boehringer Ingelheim International GmbH $50.0010/11/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1017331455 CMS
Boehringer Ingelheim International GmbH $50.0010/11/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1017331459 CMS
Boehringer Ingelheim International GmbH $117.1110/11/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1017331461 CMS
Boehringer Ingelheim International GmbH $258.2310/11/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1017333341 CMS
Boehringer Ingelheim International GmbH $145.0010/11/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1017334741 CMS
Boehringer Ingelheim International GmbH $50.0010/11/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1017334747 CMS
Boehringer Ingelheim International GmbH $379.5209/18/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1017331457 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2023 $1,623.09 13

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2023
Source files and profile matching
Source files
Dataset page · Bulk file · PY2023
Generated from
OP_DTL_GNRL_PGYR2023_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $446,097.75 182
PY2024 Principal investigator $570,274.40 11
PY2023 Principal investigator $967,927.34 8
PY2021 Principal investigator $53,900.58 27
PY2020 Principal investigator $27,098.70 23

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

182 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Merck Sharp & Dohme LLC $1,102.20 12/31/2025 Non-covered Recipient Entity
EmVenio Research
A Phase 3, Randomized, Double-blind, Active Comparator-controlled Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of V116 in Pneumococcal Vaccine-na ve Adults 18 to 64 years of Age With Increased Risk for Pneumococcal Disease No dispute reported 06/30/2026 1232934312
Principal investigator 1 Boehringer Ingelheim International GmbH $39.96 12/17/2025 Non-covered Recipient Entity
Emvenio Research
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220742895
Principal investigator 1 Boehringer Ingelheim International GmbH $109.50 12/17/2025 Non-covered Recipient Entity
Emvenio Research
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220742897
Principal investigator 1 Boehringer Ingelheim International GmbH $5.22 12/17/2025 Non-covered Recipient Entity
Emvenio Research
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220742899
Principal investigator 1 Boehringer Ingelheim International GmbH $12.42 12/17/2025 Non-covered Recipient Entity
Emvenio Research
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220742901
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 12/01/2025 Non-covered Recipient Entity
Emvenio Research
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220742739
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 12/01/2025 Non-covered Recipient Entity
Emvenio Research
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220742741
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 12/01/2025 Non-covered Recipient Entity
Emvenio Research
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220742893
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $26,307.00 11/26/2025 Non-covered Recipient Entity
EmVenio Research Inc
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220808378
Principal investigator 1 Boehringer Ingelheim International GmbH $255.50 11/19/2025 Non-covered Recipient Entity
Emvenio Research
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220742743
Principal investigator 1 Boehringer Ingelheim International GmbH $12.18 11/19/2025 Non-covered Recipient Entity
Emvenio Research
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220742745
Principal investigator 1 Boehringer Ingelheim International GmbH $16.56 11/19/2025 Non-covered Recipient Entity
Emvenio Research
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220742747
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 11/01/2025 Non-covered Recipient Entity
Emvenio Research
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220742737
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 11/01/2025 Non-covered Recipient Entity
Emvenio Research
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220742889
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 11/01/2025 Non-covered Recipient Entity
Emvenio Research
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220742891
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $1,500.00 10/24/2025 Non-covered Recipient Entity
EmVenio Research Inc
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220808376
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $25,057.00 10/24/2025 Non-covered Recipient Entity
EmVenio Research Inc
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220808408
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $26,007.00 10/24/2025 Non-covered Recipient Entity
EmVenio Research Inc
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220808410
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $587.37 10/03/2025 Non-covered Recipient Entity
EmVenio Research Inc
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220808412
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 10/01/2025 Non-covered Recipient Entity
Emvenio Research
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220742735
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 10/01/2025 Non-covered Recipient Entity
Emvenio Research
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220742885
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 10/01/2025 Non-covered Recipient Entity
Emvenio Research
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220742887
Principal investigator 1 Boehringer Ingelheim International GmbH $36.50 09/24/2025 Non-covered Recipient Entity
Emvenio Research
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220742733
Principal investigator 1 Boehringer Ingelheim International GmbH $146.00 09/24/2025 Non-covered Recipient Entity
Emvenio Research
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220742883
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $450.00 09/24/2025 Non-covered Recipient Entity
EmVenio Research Inc
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220808406
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $350.00 09/23/2025 Non-covered Recipient Entity
EmVenio Research Inc
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220808404
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $27,507.00 09/22/2025 Non-covered Recipient Entity
EmVenio Research Inc
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220808368
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $3,250.00 09/22/2025 Non-covered Recipient Entity
EmVenio Research Inc
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220808370
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $24,907.00 09/22/2025 Non-covered Recipient Entity
EmVenio Research Inc
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220808402
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $1,800.00 09/15/2025 Non-covered Recipient Entity
EmVenio Research Inc
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220808360
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $24,907.00 09/15/2025 Non-covered Recipient Entity
EmVenio Research Inc
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220808362
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $2,550.00 09/10/2025 Non-covered Recipient Entity
EmVenio Research Inc
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220808364
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $27,607.00 09/10/2025 Non-covered Recipient Entity
EmVenio Research Inc
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220808366
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $24,907.00 09/10/2025 Non-covered Recipient Entity
EmVenio Research Inc
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220808394
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $24,907.00 09/10/2025 Non-covered Recipient Entity
EmVenio Research Inc
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220808396
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $250.00 09/10/2025 Non-covered Recipient Entity
EmVenio Research Inc
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220808398
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $150.00 09/10/2025 Non-covered Recipient Entity
EmVenio Research Inc
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220808400
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $269.00 09/10/2025 Non-covered Recipient Entity
Emvenio Research
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220810794
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $269.00 09/10/2025 Non-covered Recipient Entity
Emvenio Research
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220810796
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $269.00 09/10/2025 Non-covered Recipient Entity
Emvenio Research
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220810798
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $269.00 09/10/2025 Non-covered Recipient Entity
Emvenio Research
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220810800
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $450.00 09/08/2025 Non-covered Recipient Entity
EmVenio Research Inc
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220808388
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $450.00 09/08/2025 Non-covered Recipient Entity
EmVenio Research Inc
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220808390
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $1,950.00 09/03/2025 Non-covered Recipient Entity
EmVenio Research Inc
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220808372
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $24,907.00 09/03/2025 Non-covered Recipient Entity
EmVenio Research Inc
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220808374
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 09/01/2025 Non-covered Recipient Entity
Emvenio Research
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220742709
Principal investigator 1 Boehringer Ingelheim International GmbH $30.79 09/01/2025 Non-covered Recipient Entity
Emvenio Research
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220742853
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 09/01/2025 Non-covered Recipient Entity
Emvenio Research
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220742855
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 09/01/2025 Non-covered Recipient Entity
Emvenio Research
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220742869
Principal investigator 1 Boehringer Ingelheim International GmbH $23.32 08/26/2025 Non-covered Recipient Entity
Emvenio Research
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220742721
Principal investigator 1 Boehringer Ingelheim International GmbH $365.00 08/26/2025 Non-covered Recipient Entity
Emvenio Research
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220742723
Principal investigator 1 Boehringer Ingelheim International GmbH $663.30 08/26/2025 Non-covered Recipient Entity
Emvenio Research
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220742725
Principal investigator 1 Boehringer Ingelheim International GmbH $10.00 08/26/2025 Non-covered Recipient Entity
Emvenio Research
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220742727
Principal investigator 1 Boehringer Ingelheim International GmbH $10.44 08/26/2025 Non-covered Recipient Entity
Emvenio Research
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220742729
Principal investigator 1 Boehringer Ingelheim International GmbH $4.14 08/26/2025 Non-covered Recipient Entity
Emvenio Research
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220742731
Principal investigator 1 Boehringer Ingelheim International GmbH $19.98 08/26/2025 Non-covered Recipient Entity
Emvenio Research
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220742875
Principal investigator 1 Boehringer Ingelheim International GmbH $693.50 08/26/2025 Non-covered Recipient Entity
Emvenio Research
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220742877
Principal investigator 1 Boehringer Ingelheim International GmbH $27.84 08/26/2025 Non-covered Recipient Entity
Emvenio Research
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220742879
Principal investigator 1 Boehringer Ingelheim International GmbH $28.98 08/26/2025 Non-covered Recipient Entity
Emvenio Research
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220742881
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $24,907.00 08/21/2025 Non-covered Recipient Entity
EmVenio Research Inc
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220808386
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $250.00 08/04/2025 Non-covered Recipient Entity
EmVenio Research Inc
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220808392
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 08/01/2025 Non-covered Recipient Entity
Emvenio Research
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220742707
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 08/01/2025 Non-covered Recipient Entity
Emvenio Research
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220742867
Principal investigator 1 Boehringer Ingelheim International GmbH $19.98 07/28/2025 Non-covered Recipient Entity
Emvenio Research
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220742719
Principal investigator 1 Boehringer Ingelheim International GmbH $93.28 07/28/2025 Non-covered Recipient Entity
Emvenio Research
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220742871
Principal investigator 1 Boehringer Ingelheim International GmbH $39.96 07/28/2025 Non-covered Recipient Entity
Emvenio Research
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220742873
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $24,907.00 07/21/2025 Non-covered Recipient Entity
EmVenio Research Inc
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220808382
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $300.00 07/21/2025 Non-covered Recipient Entity
EmVenio Research Inc
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220808384
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 07/01/2025 Non-covered Recipient Entity
Emvenio Research
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220742711
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 07/01/2025 Non-covered Recipient Entity
Emvenio Research
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220742713
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 07/01/2025 Non-covered Recipient Entity
Emvenio Research
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220742715
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 07/01/2025 Non-covered Recipient Entity
Emvenio Research
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220742717
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 07/01/2025 Non-covered Recipient Entity
Emvenio Research
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220742857
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 07/01/2025 Non-covered Recipient Entity
Emvenio Research
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220742859
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 07/01/2025 Non-covered Recipient Entity
Emvenio Research
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220742861
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 07/01/2025 Non-covered Recipient Entity
Emvenio Research
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220742863
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 07/01/2025 Non-covered Recipient Entity
Emvenio Research
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220742865
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $24,907.00 06/28/2025 Non-covered Recipient Entity
EmVenio Research Inc
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220808358
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $2,150.00 06/27/2025 Non-covered Recipient Entity
EmVenio Research Inc
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220808352
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $1,373.42 06/27/2025 Non-covered Recipient Entity
EmVenio Research Inc
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220808354
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $1,650.00 06/27/2025 Non-covered Recipient Entity
EmVenio Research Inc
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220808356
Principal investigator 1 Boehringer Ingelheim International GmbH $530.64 06/24/2025 Non-covered Recipient Entity
Emvenio Research
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220742705
Principal investigator 1 Boehringer Ingelheim International GmbH $93.28 06/24/2025 Non-covered Recipient Entity
Emvenio Research
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220742843
Principal investigator 1 Boehringer Ingelheim International GmbH $39.96 06/24/2025 Non-covered Recipient Entity
Emvenio Research
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220742845
Principal investigator 1 Boehringer Ingelheim International GmbH $438.00 06/24/2025 Non-covered Recipient Entity
Emvenio Research
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220742847
Principal investigator 1 Boehringer Ingelheim International GmbH $17.40 06/24/2025 Non-covered Recipient Entity
Emvenio Research
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220742849
Principal investigator 1 Boehringer Ingelheim International GmbH $24.84 06/24/2025 Non-covered Recipient Entity
Emvenio Research
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220742851
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $8.60 06/12/2025 Non-covered Recipient Entity
Emvenio Research
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220810804
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 06/01/2025 Non-covered Recipient Entity
Emvenio Research
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220742689
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 06/01/2025 Non-covered Recipient Entity
Emvenio Research
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220742691
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 06/01/2025 Non-covered Recipient Entity
Emvenio Research
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220742693
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 06/01/2025 Non-covered Recipient Entity
Emvenio Research
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220742695
Principal investigator 1 Boehringer Ingelheim International GmbH $86.00 06/01/2025 Non-covered Recipient Entity
Emvenio Research
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220742819
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 06/01/2025 Non-covered Recipient Entity
Emvenio Research
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220742821
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 06/01/2025 Non-covered Recipient Entity
Emvenio Research
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220742823
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 06/01/2025 Non-covered Recipient Entity
Emvenio Research
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220742825
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 06/01/2025 Non-covered Recipient Entity
Emvenio Research
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220742827
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 06/01/2025 Non-covered Recipient Entity
Emvenio Research
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220742829
Principal investigator 1 Boehringer Ingelheim International GmbH $159.84 05/27/2025 Non-covered Recipient Entity
Emvenio Research
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220742837
Principal investigator 1 Boehringer Ingelheim International GmbH $36.50 05/27/2025 Non-covered Recipient Entity
Emvenio Research
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220742839
Principal investigator 1 Boehringer Ingelheim International GmbH $1.74 05/27/2025 Non-covered Recipient Entity
Emvenio Research
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220742841
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $150.00 05/12/2025 Non-covered Recipient Entity
Emvenio Research
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220810792
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $150.00 05/12/2025 Non-covered Recipient Entity
Emvenio Research
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220810806
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $407.14 05/06/2025 Non-covered Recipient Entity
Emvenio Research
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220810790
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $1,889.00 05/04/2025 Non-covered Recipient Entity
EmVenio Research Inc
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220808350
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 05/01/2025 Non-covered Recipient Entity
Emvenio Research
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220742681
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 05/01/2025 Non-covered Recipient Entity
Emvenio Research
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220742683
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 05/01/2025 Non-covered Recipient Entity
Emvenio Research
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220742685
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 05/01/2025 Non-covered Recipient Entity
Emvenio Research
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220742687
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 05/01/2025 Non-covered Recipient Entity
Emvenio Research
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220742805
Principal investigator 1 Boehringer Ingelheim International GmbH $86.00 05/01/2025 Non-covered Recipient Entity
Emvenio Research
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220742807
Principal investigator 1 Boehringer Ingelheim International GmbH $86.00 05/01/2025 Non-covered Recipient Entity
Emvenio Research
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220742809
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 05/01/2025 Non-covered Recipient Entity
Emvenio Research
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220742811
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 05/01/2025 Non-covered Recipient Entity
Emvenio Research
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220742813
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 05/01/2025 Non-covered Recipient Entity
Emvenio Research
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220742815
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 05/01/2025 Non-covered Recipient Entity
Emvenio Research
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220742817
Principal investigator 1 Boehringer Ingelheim International GmbH $39.96 04/23/2025 Non-covered Recipient Entity
Emvenio Research
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220742697
Principal investigator 1 Boehringer Ingelheim International GmbH $36.50 04/23/2025 Non-covered Recipient Entity
Emvenio Research
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220742699
Principal investigator 1 Boehringer Ingelheim International GmbH $12.00 04/23/2025 Non-covered Recipient Entity
Emvenio Research
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220742701
Principal investigator 1 Boehringer Ingelheim International GmbH $1.74 04/23/2025 Non-covered Recipient Entity
Emvenio Research
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220742703
Principal investigator 1 Boehringer Ingelheim International GmbH $19.98 04/23/2025 Non-covered Recipient Entity
Emvenio Research
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220742831
Principal investigator 1 Boehringer Ingelheim International GmbH $73.00 04/23/2025 Non-covered Recipient Entity
Emvenio Research
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220742833
Principal investigator 1 Boehringer Ingelheim International GmbH $3.48 04/23/2025 Non-covered Recipient Entity
Emvenio Research
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220742835
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $1,500.00 04/23/2025 Non-covered Recipient Entity
EmVenio Research Inc
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220808346
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $24,907.00 04/23/2025 Non-covered Recipient Entity
EmVenio Research Inc
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220808348
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 04/01/2025 Non-covered Recipient Entity
Emvenio Research
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220742673
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 04/01/2025 Non-covered Recipient Entity
Emvenio Research
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220742675
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 04/01/2025 Non-covered Recipient Entity
Emvenio Research
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220742677
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 04/01/2025 Non-covered Recipient Entity
Emvenio Research
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220742679
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 04/01/2025 Non-covered Recipient Entity
Emvenio Research
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220742793
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 04/01/2025 Non-covered Recipient Entity
Emvenio Research
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220742795
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 04/01/2025 Non-covered Recipient Entity
Emvenio Research
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220742797
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 04/01/2025 Non-covered Recipient Entity
Emvenio Research
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220742799
Principal investigator 1 Boehringer Ingelheim International GmbH $86.00 04/01/2025 Non-covered Recipient Entity
Emvenio Research
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220742801
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 04/01/2025 Non-covered Recipient Entity
Emvenio Research
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220742803
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $24,907.00 04/01/2025 Non-covered Recipient Entity
EmVenio Research Inc
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220808344
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $1,421.93 03/30/2025 Non-covered Recipient Entity
EmVenio Research Inc
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220808340
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $1,350.00 03/30/2025 Non-covered Recipient Entity
EmVenio Research Inc
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220808342
Principal investigator 1 Boehringer Ingelheim International GmbH $73.00 03/25/2025 Non-covered Recipient Entity
Emvenio Research
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220742669
Principal investigator 1 Boehringer Ingelheim International GmbH $3.48 03/25/2025 Non-covered Recipient Entity
Emvenio Research
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220742671
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $51.60 03/11/2025 Non-covered Recipient Entity
Emvenio Research
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220810788
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $17.20 03/07/2025 Non-covered Recipient Entity
Emvenio Research
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220810802
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 03/01/2025 Non-covered Recipient Entity
Emvenio Research
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220742655
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 03/01/2025 Non-covered Recipient Entity
Emvenio Research
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220742657
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 03/01/2025 Non-covered Recipient Entity
Emvenio Research
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220742659
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 03/01/2025 Non-covered Recipient Entity
Emvenio Research
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220742661
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 03/01/2025 Non-covered Recipient Entity
Emvenio Research
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220742769
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 03/01/2025 Non-covered Recipient Entity
Emvenio Research
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220742771
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 03/01/2025 Non-covered Recipient Entity
Emvenio Research
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220742773
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 03/01/2025 Non-covered Recipient Entity
Emvenio Research
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220742775
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 03/01/2025 Non-covered Recipient Entity
Emvenio Research
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220742777
Principal investigator 1 Boehringer Ingelheim International GmbH $328.50 02/25/2025 Non-covered Recipient Entity
Emvenio Research
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220742785
Principal investigator 1 Boehringer Ingelheim International GmbH $707.52 02/25/2025 Non-covered Recipient Entity
Emvenio Research
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220742787
Principal investigator 1 Boehringer Ingelheim International GmbH $10.44 02/25/2025 Non-covered Recipient Entity
Emvenio Research
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220742789
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 02/01/2025 Non-covered Recipient Entity
Emvenio Research
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220742647
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 02/01/2025 Non-covered Recipient Entity
Emvenio Research
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220742649
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 02/01/2025 Non-covered Recipient Entity
Emvenio Research
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220742651
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 02/01/2025 Non-covered Recipient Entity
Emvenio Research
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220742653
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 02/01/2025 Non-covered Recipient Entity
Emvenio Research
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220742757
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 02/01/2025 Non-covered Recipient Entity
Emvenio Research
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220742759
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 02/01/2025 Non-covered Recipient Entity
Emvenio Research
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220742761
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 02/01/2025 Non-covered Recipient Entity
Emvenio Research
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220742763
Principal investigator 1 Boehringer Ingelheim International GmbH $86.00 02/01/2025 Non-covered Recipient Entity
Emvenio Research
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220742765
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 02/01/2025 Non-covered Recipient Entity
Emvenio Research
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220742767
Principal investigator 1 Boehringer Ingelheim International GmbH $36.50 01/27/2025 Non-covered Recipient Entity
Emvenio Research
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220742663
Principal investigator 1 Boehringer Ingelheim International GmbH $1.74 01/27/2025 Non-covered Recipient Entity
Emvenio Research
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220742665
Principal investigator 1 Boehringer Ingelheim International GmbH $4.14 01/27/2025 Non-covered Recipient Entity
Emvenio Research
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220742667
Principal investigator 1 Boehringer Ingelheim International GmbH $182.50 01/27/2025 Non-covered Recipient Entity
Emvenio Research
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220742779
Principal investigator 1 Boehringer Ingelheim International GmbH $8.70 01/27/2025 Non-covered Recipient Entity
Emvenio Research
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220742781
Principal investigator 1 Boehringer Ingelheim International GmbH $16.56 01/27/2025 Non-covered Recipient Entity
Emvenio Research
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220742783
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $450.00 01/10/2025 Non-covered Recipient Entity
EmVenio Research Inc
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220808380
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $1,500.00 01/09/2025 Non-covered Recipient Entity
EmVenio Research Inc
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220808336
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $24,907.00 01/09/2025 Non-covered Recipient Entity
EmVenio Research Inc
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220808338
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 01/01/2025 Non-covered Recipient Entity
Emvenio Research
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220742639
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 01/01/2025 Non-covered Recipient Entity
Emvenio Research
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220742641
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 01/01/2025 Non-covered Recipient Entity
Emvenio Research
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220742643
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 01/01/2025 Non-covered Recipient Entity
Emvenio Research
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus No dispute reported 06/30/2026 1220742645
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 01/01/2025 Non-covered Recipient Entity
Emvenio Research
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220742749
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 01/01/2025 Non-covered Recipient Entity
Emvenio Research
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220742751
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 01/01/2025 Non-covered Recipient Entity
Emvenio Research
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220742753
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 01/01/2025 Non-covered Recipient Entity
Emvenio Research
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220742755
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 01/01/2025 Non-covered Recipient Entity
Emvenio Research
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes No dispute reported 06/30/2026 1220742791